Klifo

Executive Summary

Klifo, a Danish drug development consultancy and Clinical Trial Supply (CTS) organization founded in 1995, provides strategic advisory and end-to-end supply chain solutions for pharmaceutical and biotech clients. Operating from Copenhagen, the company supports clients from early development through post-market activities via its two divisions: KLIFO Advisory and KLIFO Clinical Trial Supply. With nearly three decades of experience, Klifo has established itself as a reliable partner in the highly regulated pharmaceutical industry, offering expertise in clinical trial logistics, regulatory compliance, and global supply chain management. The company's service model addresses the growing complexity of decentralized and globalized clinical trials, positioning it well to benefit from increased R&D spending and outsourcing trends. Despite being private and lacking recent fundraising or pipeline milestones, Klifo's revenue stability and long-standing client relationships suggest a resilient business model. However, limited visibility into financials and competitive pressures from larger CROs and CTS providers constrain upside conviction. The company's strategic focus on personalized medicine and cell/gene therapy supply chains could drive future growth, but near-term catalysts are primarily operational.

Upcoming Catalysts (preview)

• Q3 2026Expansion into cell and gene therapy supply chain services60% success
• TBDStrategic partnership with a mid-sized biotech for global trial supply50% success
• Q3 2026Launch of a digital supply chain tracking platform45% success